click here for podcast download
CCTR interviews Laura Thrall, CEO of CureSearch since 2012, with five years of refining purpose, innovation, and efficiency in the medical research industry to benefit pediatric cancer research funding. The primary goal and measure of the success of any new policy should be evident in patient care, access, and improved treatment options for children. The history of CureSearch is highlighted, and the intricacy of the industry is illuminated with more to tackle than simply increasing the 4% of the Federal funds for cancer research designated for pediatric research. Advocacy, the importance of the pharmaceutical industry, and pragmatic solutions to the long-standing difficulty to improving treatment options for children are highlighted.
